Date | Price Target | Rating | Analyst |
---|---|---|---|
7/3/2024 | $8.00 | Neutral | H.C. Wainwright |
3/4/2024 | $40.00 | Overweight | Morgan Stanley |
3/4/2024 | $39.00 | Overweight | JP Morgan |
3/4/2024 | $44.00 | Overweight | Wells Fargo |
3/4/2024 | $48.00 | Outperform | Leerink Partners |
– Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product Planning and Franchise Leadership Experience, Including Successful Launches for CAR T Pioneer in Hematology – Christi Shaw, Life Sciences Leader at Multiple Major Pharmaceutical and Biotech Companies and Across Therapeutic Areas, Appointed to Board of Directors – Together Strengthen Leadership as Trailblazers of Cell Therapy with Extensive Experience Leading Through Clinical Development, Manufacturing, Commercial Launch and Expansion EMERYVILLE, Calif., Sept. 16, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharma
EMERYVILLE, Calif., Aug. 21, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today that the company's executives will participate in the following investor events: Investor Conference Details: Morgan Stanley Global Healthcare Conference in New York, NY on September 4, 2024Format: Fireside Chat with Mike Ulz at 11:30 am EDT and host investor meetingsWells Fargo Healthcare Conference in Boston, MA on September
Actively recruiting clinical trials in neurology and rheumatology with KYV-101No severe ICANS or CRS reported in first 36 autoimmune disease patients treated with KYV-101Received FDA RMAT Designation for KYV-101 for treatment of patients with Stiff-Person SyndromeReceived FDA RMAT Designation for KYV-101 for treatment of patients with Myasthenia GravisReported clinical experience with first KYV-101 patient disease-free at 1 year after treatmentEMERYVILLE, Calif., Aug. 12, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today reporte
H.C. Wainwright initiated coverage of Kyverna Therapeutics with a rating of Neutral and set a new price target of $8.00
Morgan Stanley initiated coverage of Kyverna Therapeutics with a rating of Overweight and set a new price target of $40.00
JP Morgan initiated coverage of Kyverna Therapeutics with a rating of Overweight and set a new price target of $39.00
A revolutionary cell-based gene therapy is showing promise for treating autoimmune diseases. Professor Georg Schett, a rheumatologist at University Hospital Erlangen in eastern Germany, used chimeric antigen receptor (CAR-T) cell therapy, typically used for blood cancers, for autoimmune conditions like lupus, when the immune system attacks healthy cells and tissues by mistake. This attack causes inflammation. The Financial Times writes that the early success of CAT-T therapy has reignited discussions about its potential beyond blood cancers, though challenges remain. Professor Georg Schett noted that this approach could revolutionize autoimmune disease treatment, providing a one-tim
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral and maintains $8 price target.
With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Bank of America Corporation (NYSE:BAC) to report quarterly earnings at 80 cents per share on revenue of $25.22 billion before the opening bell. Bank of America shares gained 0.1% to $41.94 in after-hours trading. FB Financial Corporation (NYSE:FBK) posted better-than-expected results for its second quarter on Monday. FB Financial shares rose 0.5% to $43.03 in the after-hours trading session. Analysts are expecting Morgan Stanley (NYSE:MS) to post quarterly earnings at $1.65 per share on revenue of $14.3 billion. The company will r
8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
10-Q - Kyverna Therapeutics, Inc. (0001994702) (Filer)
8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
SC 13D - Kyverna Therapeutics, Inc. (0001994702) (Subject)
SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)
SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)
The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti CD19 CAR T-cell therapy in up to 12 study participants The clinical study will be supported by cutting edge correlative studies funded through a parallel research collaboration between Kyverna and Stanford University The agreements further expand the scale of ongoing clinical studies assessing the potential therapeutic effects of KYV-101 in multiple diseases and locations around the world EMERYVILLE, Calif., March 7, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapie
Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR-T cells Kyverna to host a conference call on April 16 to review recent named-patient experience in patients suffering from multiple sclerosis and myasthenia gravis EMERYVILLE, Calif., April 11, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today its attendance at the 2024 annual meeting of the American Academy of Neurology to be held in Denver, Colorado, starting